logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Menorrhagia

    FiltersReset Filters
    7 results

    • liletta

      (Levonorgestrel)
      Allergan, Inc.
      Usage: LILETTA is indicated for contraception to prevent pregnancy for up to 8 years and for the treatment of heavy menstrual bleeding for up to 5 years in patients using intrauterine contraception, with replacement required after 5 years if continued treatment is necessary.

    • mirena

      (Levonorgestrel)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Mirena is indicated for contraception, preventing pregnancy for up to 8 years, and for treating heavy menstrual bleeding for up to 5 years in women using it as their contraceptive method. Replacement is suggested at the end of the respective durations if treatment continues.

    • myfembree

      (relugolix, estradiol hemihydrate, and norethindrone acetate)
      Sumitomo Pharma America, Inc
      Usage: MYFEMBREE is indicated for managing heavy menstrual bleeding due to uterine leiomyomas and for moderate to severe pain associated with endometriosis in premenopausal women. Its use should be limited to 24 months to mitigate the risk of irreversible bone loss.

    • natazia

      (estradiol valerate and estradiol valerate/dienogest)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Natazia® is indicated for preventing pregnancy in women and for treating heavy menstrual bleeding in those without organic pathology who prefer an oral contraceptive. Efficacy in women with a BMI over 30 kg/m² has not been evaluated.

    • oriahnn

      (Elagolix and Estradiol and Norethisterone)
      AbbVie Inc.
      Usage: ORIAHNN is indicated for managing heavy menstrual bleeding associated with uterine fibroids in premenopausal women. It should be limited to 24 months of use due to the risk of potential irreversible bone loss.

    • progesterone

      (PROGESTERONE)
      XIROMED, LLC
      Usage: This drug is indicated for the treatment of amenorrhea and abnormal uterine bleeding caused by hormonal imbalances, provided there are no underlying organic conditions like submucous fibroids or uterine cancer.

    • tranexamic acid

      (Tranexamic Acid)
      ANI Pharmaceuticals Inc
      Usage: Tranexamic Acid Tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females who are of reproductive potential.